GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Foundation Medicine Inc (NAS:FMI) » Definitions » Cash-to-Debt

Foundation Medicine (Foundation Medicine) Cash-to-Debt : 0.49 (As of Jun. 2018)


View and export this data going back to 2013. Start your Free Trial

What is Foundation Medicine Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Foundation Medicine's cash to debt ratio for the quarter that ended in Jun. 2018 was 0.49.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Foundation Medicine couldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2018.

The historical rank and industry rank for Foundation Medicine's Cash-to-Debt or its related term are showing as below:

FMI's Cash-to-Debt is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 1.32
* Ranked among companies with meaningful Cash-to-Debt only.

Foundation Medicine Cash-to-Debt Historical Data

The historical data trend for Foundation Medicine's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Foundation Medicine Cash-to-Debt Chart

Foundation Medicine Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Cash-to-Debt
Get a 7-Day Free Trial 82.92 No Debt No Debt No Debt 1.19

Foundation Medicine Quarterly Data
Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only No Debt No Debt 1.19 0.67 0.49

Competitive Comparison of Foundation Medicine's Cash-to-Debt

For the Diagnostics & Research subindustry, Foundation Medicine's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Foundation Medicine's Cash-to-Debt Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Foundation Medicine's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Foundation Medicine's Cash-to-Debt falls into.


Foundation Medicine Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Foundation Medicine's Cash to Debt Ratio for the fiscal year that ended in Dec. 2017 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=71.404 / (0 + 60)
=1.19

Foundation Medicine's Cash to Debt Ratio for the quarter that ended in Jun. 2018 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=53.418 / (0 + 110)
=0.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Foundation Medicine  (NAS:FMI) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Foundation Medicine Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Foundation Medicine's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Foundation Medicine (Foundation Medicine) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Foundation Medicine Inc (NAS:FMI) » Definitions » Cash-to-Debt
Comparable Companies
SYNH MIL:DIA GH BRKR SHSE:603658 SZSE:300676 PRAH CRL NEOG ICLR QDEL GHDX SHSE:603882 MYGN BSP:DASA3 XPAR:ERF MEDP NEO NVTA BEAT
Traded in Other Exchanges
N/A
Address
Website
http://www.foundationmedicine.com
Foundation Medicine Inc is a molecular diagnostics company that specializes in the evaluation and treatment of cancer. Its products provide genetic information about a patient's cancer that is used by physicians to inform clinical decisions and by biopharmaceutical companies to develop targeted oncology therapies. Foundation Medicine's core molecular information products include FoundationOne, for solid tumors, and FoundationOne Heme, for blood-based cancers and hematologic malignancies. The vast majority of the firm's revenue is generated within the United States.
Executives
Alexis Borisy director C/O COMBINATORX, INCORPORATED, 245 FIRST STREET, 16TH FLOOR, CAMBRIDGE MA 02142
Vincent A. Miller officer: Chief Medical Officer C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Michael J Pellini director 222 DUTTON MILL RD, WILLISTOWN PA 19380
Jason Ryan officer: Chief Financial Officer C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Troy Cox director, officer: President and CEO C/O FOUNDATION MEDICINE, INC., C/O FOUNDATION MEDICINE, INC., 150 SECON, CAMBRIDGE MA 02141
Robert W. Hesslein officer: SVP and General Counsel C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Thomas Civik officer: Chief Commercial Officer C/O FOUNDATION MEDICINE, INC., 150 SECOND STREET, CAMBRIDGE MA 02141
Evan/ Fa Jones director C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
Michael R Dougherty director C/O ADOLOR CORP, 700 PENNSYLVANIA DR, EXTON PA 19341
Roche Finance Ltd director, 10 percent owner, other: See footnote (1) C/O HOFFMAN LA ROCHE, 124 GRENSACHERSTRASSE CH 4002, BASEL SWITZERLAND V8
Roche Holding Ltd director, 10 percent owner, other: See footnote (1) ROCHE HOLDING, LTD., GRENZACHERSTRASSE 124, BASEL V8 CH-4070
David P Schenkein director C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Robert I Tepper 10 percent owner 201 BROOKLINE AVE, SUITE 1401, BOSTON MA 02215
Mark J Levin 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Third Rock Ventures Gp, L.p. 10 percent owner C/O THIRD ROCK VENTURES, 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116